OBJECTIVE: @entity1 in the postpartum period are at high risk for complications from @entity683 . Pharmacokinetic data of @entity26812 in postpartum @entity1 , however, are lacking. STUDY DESIGN: Seven healthy @entity1 within 48 hours of delivery were recruited. Each @entity1 received 75 mg of @entity26812 . Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for @entity684 and @entity26591 levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (C(max)), time to maximum concentration, and half-life were estimated. RESULTS: @entity26812 and @entity26591 were found in breast milk, although later and in lower levels than that found in plasma. The C(max) and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. CONCLUSION: @entity26591 was present in breast milk but in concentrations significantly lower than considered therapeutic in @entity1 .

Pharmacokinetics of XXXX in breast milk and maternal plasma.

@entity1 :: ('9606', 'Species') :: ['women', 'woman', 'patients', 'Women', 'infants'] @entity26591 :: ('MESH:C535162', 'Chemical') :: ['oseltamivir carboxylate', 'Oseltamivir carboxylate'] @entity684 :: ('MESH:D053139', 'Chemical') :: ['oseltamivir'] @entity26812 :: ('CHEBI:7799', 'Chemical') :: ['Oseltamivir phosphate', 'oseltamivir phosphate'] @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']
@entity684 :: (MESH:D053139,Chemical) :: ['oseltamivir']
